[Comparative studies on oral glucose tolerance and serum lipids under the influence of a new oral contraceptive (SH B 209 AB: 2 mg cyproterone acetate + 0.05 mg ethinyl estradiol), the combination D-norgestrel/ethinyl estradiol and in a control group (author's transl)].
24 healthy women given the combination of cyproterone acetate (2 mg) + ethynyl estradiol (0.05 mg) [SH B 209 AB] and D-norgestrel (0.25 mg) + ethinyl estradiol (0.05 mg) [Neogynon] were compared with a control group in oral glucose tolerance tests. The volunteers were divided into three groups. Two received alternately both preparations with each treatment cycle preceded by one cycle without medication. The third group served as an independent control. On the 25th day of each cycle blood was withdrawn before and 15, 30, 45, 60, 90 and 120 min after the carbohydrate load. Blood glucose and insulin and free fatty acids in serum were determined. Fasting values of triglycerides and cholesterol in serum were determined. The following results were obtained: 1. The mean fasting levels of blood glucose, serum insulin and free fatty acids were unchanged. 2. The total area under the blood glucose curve over the initial value was not altered 2 h after treatment with SH B 209 AB or Neogynon. The total area under the insulin and free fatty acids curves were also unchanged after the oral glucose load. 3. There was no change in serum cholesterol. 4. Serum triglycerides were significantly increased after SH B 209 AB. 5. The implications of the structural differences between both gestagens are discussed.
D001786:Blood Glucose / Q000378:metabolism*; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D003534:Cyproterone / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D008055:Lipids / Q000097:blood*; D009644:Norgestrel / Q000494:pharmacology*
D001786:Blood Glucose; D003277:Contraceptives, Oral, Combined; D008055:Lipids; D009644:Norgestrel; D004997:Ethinyl Estradiol; D003534:Cyproterone
Vergleichende Untersuchungen der oralen Glukosetoleranz und der Serumlipide unter Anwendung eines neuen oralen Kontrazeptivums (SH B 209 AB: 2 mg Cyproteronacetat + 0,05 mg Athinylöstradiol), der Kombination D-Norgestrol/Athinylöstradiol und bei einer Kontrollgruppe